GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

Sponsor
Grit Biotechnology
Study ID
NCT07122076
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Autoimmune Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • GT719 Injection — BIOLOGICAL
    GT719 Injection

Study Details

This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.

Key Dates

First listed
Aug 14, 2025
Start date
Aug 22, 2025
Status verified
Sep 2025
Primary completion
Aug 21, 2028
Completion
Aug 21, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: GT719 Injection treatment group
    GT719 Injection

Primary Outcome Measure

Proportion of participants experiencing dose limiting toxicity [ Time Frame: 28 days ]

Central Contacts

Related Studies